SLC5A2 and asthma: Placebo-controlled cardiovascular (or cardiorenal) outcome trials reported that SGLT-2 inhibitors (OR, 0.59; 95% CI, 0.38-0.93) were significantly associated with a reduced risk of asthma compared with placebo, and SGLT-2 inhibitors may prevent asthma (Wang et al., 2022) and may also be useful in obese asthma due to their weight loss profile.